Good
Mostly Aligned
Patient Risk:
Low
Summary
Most safety-related items (PSA interpretation, common adverse reactions including sexual effects, pregnancy/transdermal exposure, blood donation deferral concept, and need to handle leaking capsules by pregnant women) and many efficacy/administration statements align with the provided label excerpts. However, several statements about combination therapy, timing of symptom improvement, and general prescribing practices are either not supported by the supplied excerpts or are overstated, lowering overall alignment.
Category Scores
Accurate Statements
Avodart (dutasteride) is a prescription medicine used mainly for treating benign prostatic hyperplasia (enlarged prostate).
Section 1.1 indicates AVODART for symptomatic BPH in men with an enlarged prostate.
Dutasteride works by blocking enzymes that convert testosterone into dihydrotestosterone (DHT).
Section 8.1 states AVODART is a 5 alpha-reductase inhibitor that prevents conversion of testosterone to dihydrotestosterone (DHT).
Blocking conversion of testosterone to DHT helps shrink the prostate.
Section 14.1 states AVODART decreases prostate volume.
Shrinking the prostate reduces BPH-related urinary symptoms.
Section 1.1 lists improve symptoms; Section 14.1 states improves BPH-related symptoms.
Avodart is often used as part of combination treatment for BPH depending on symptoms and prostate size.
Section 1.2 indicates AVODART in combination with tamsulosin for symptomatic BPH in men with an enlarged prostate. (Label does not support 'often' or 'depending on symptoms and prostate size' as stated.)
Common concerns with dutasteride/Avodart include sexual side effects such as reduced libido.
Section 6.1 lists decreased libido as a most common adverse reaction.
Common concerns with dutasteride/Avodart include erectile changes.
Section 6.1 lists impotence as a most common adverse reaction.
Common concerns with dutasteride/Avodart include ejaculatory changes.
Section 6.1 lists ejaculation disorders among the most common adverse reactions.
Clinicians monitor prostate-related screening considerations in people on dutasteride.
Section 5.1 provides guidance on PSA interpretation and monitoring.
People on dutasteride may need adjusted interpretation of PSA tests.
Section 5.1 explains PSA reduction (~50%), establishment of a new PSA baseline at least 3 months after starting, periodic monitoring, and doubling an isolated PSA value after 3 months.
Patients should seek prompt medical advice if they notice breast lumps or tenderness while taking dutasteride/Avodart.
Section 6.1 includes breast disorders (including breast enlargement and tenderness). The label excerpt provided does not explicitly state the 'seek prompt medical advice' instruction, but the reaction described is supported.
Unsupported Statements
Avodart is often used as part of combination treatment for BPH depending on symptoms and prostate size.
Label excerpt supports that combination with tamsulosin is indicated for symptomatic BPH in men with an enlarged prostate, but does not support frequency ('often') or the phrase 'depending on symptoms and prostate size' as a prescribing/practice rule.
Common approaches pair a 5-alpha-reductase inhibitor like dutasteride with alpha-blockers that relax prostate/urinary tract muscle.
Label excerpt only states indication for combination with tamsulosin; it does not support the mechanism description ('relax prostate/urinary tract muscle') or that this is a 'common approach'.
Symptom improvement with Avodart is typically gradual rather than immediate.
Provided label excerpts do not describe onset/timing of symptom improvement.
Patients are usually monitored over months, not days.
Label excerpts specifically discuss PSA baseline establishment 'at least 3 months' after starting and periodic monitoring thereafter, but do not support a general rule that monitoring is 'usually over months, not days' across all aspects.
Patients should seek prompt medical advice for severe or unusual reactions.
No such general patient instruction is provided in the supplied excerpts.
Patients should discuss persistent new symptoms or any changes with a prescriber.
No such general instruction is provided in the supplied excerpts.
Contradictions
Important Omissions
Transdermal exposure precautions specific to pregnancy: women who are pregnant or may be pregnant should not handle AVODART capsules; if contact with leaking capsules occurs, wash contact area immediately with soap and water; also AVODART is contraindicated in pregnancy.
Importance:
Moderate
Blood donation deferral: men should not donate blood until at least 6 months after last dose.
Importance:
Moderate
Additional warnings/precautions not mentioned: increased risk of high-grade prostate cancer (REDUCE trial findings and general statement) and semen characteristics effects.
Importance:
Moderate
Contraindication hypersensitivity to AVODART or other 5 alpha-reductase inhibitors is not addressed.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
No direct contradictions were identified. However, omissions of pregnancy/transdermal exposure and other label warnings/precautions could affect safe communication, and some generalized timing/frequency statements are unsupported.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Several unsupported generalizations (frequency of combination use; mechanism of alpha-blocker; timing of symptom improvement; generalized monitoring interval) and material omissions related to pregnancy/transdermal exposure and other key warnings/precautions.
Suggested Improvement
Limit combination and timing statements to the label-supported indication language; add label-required pregnancy/transdermal exposure and blood donation precautions; include PSA monitoring adjustment details already addressed plus other key warnings/precautions from the provided excerpts (high-grade prostate cancer risk; semen characteristics).